BIOVIC is pleased to announce the successful conclusion of an intellectual property license and technology transfer agreement with Vascular Flow Technologies (UK). This collaboration will bring the manufacture of VFT's proprietary Spiral Laminar Flow™ graft to BIOVIC's facility, and comes with full access to all their distributors and regulatory registrations, in over 20 countries. The SLF™ graft has been proven in clinical studies to have a 30-40% improvement in performance over standard PTFE grafts, making it potentially the highest performing vascular graft in the world. BIOVIC's CEO Tarun Edwin stated "this is an exciting collaboration for BIOVIC. Coupling our flagship AVATAR® graft line with a superior premium product like the Spiral Flow™ graft will quickly make us a global player in the vascular graft market" BIOVIC and VFT will work closely over the coming months to bring the AVATAR® SLF™ grafts to market by Q2 2018.
BIOVIC announces the initiation of a Post Market Comparative Clinical Study between it's flagship product the AVATAR® PTFE Vascular Graft and competitor PTFE grafts. This is a randomized, multicenter trial studying the patency of the AVATAR® graft used for dialysis (arterio-venous) access. Clinical data will be made available in the form of marketing materials as the study progresses.
BIOVIC Sdn Bhd welcomes it's first equity investment from Innocorp Ventures Sdn Bhd, a subsidiary of Agensi Innovasi Malaysia. "Agensi Inovasi Malaysia (AIM) is a statutory body created to jump start wealth creation through knowledge, technology and innovation to stimulate and develop the innovation eco-system in Malaysia. They lay down the foundation of innovation that inspire and produce a new generation of innovative entrepreneurs."
Innocorp Ventures has recognized the value BIOVIC brings to the Malaysian Bioeconomy, not only with it's products, but also with it's technology and intellectual property. Through it's investment, Innocorp has committed to seeing BIOVIC through to the commercialization phase and beyond.